Affordable Access

deepdyve-link
Publisher Website

Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results.

Authors
  • Petrova, Nataliia V1
  • Emelyanova, Alexandra G2
  • Gorbunov, Evgeniy A3
  • Edwards, Michael R4
  • Walton, Ross P5
  • Bartlett, Nathan W6
  • Aniscenko, Julia7
  • Gogsadze, Leila8
  • Bakhsoliani, Eteri9
  • Khaitov, Musa R10
  • Johnston, Sebastian L11
  • Tarasov, Sergey A12
  • Epstein, Oleg I13
  • 1 Research Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia. Electronic address: [email protected]
  • 2 Research Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia. Electronic address: [email protected]
  • 3 OOO "NPF "MATERIA MEDICA HOLDING", 129272 Moscow, Russia. Electronic address: [email protected]
  • 4 National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom. Electronic address: [email protected] , (United Kingdom)
  • 5 National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom. Electronic address: [email protected] , (United Kingdom)
  • 6 National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom. Electronic address: [email protected] , (United Kingdom)
  • 7 National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom. Electronic address: [email protected] , (United Kingdom)
  • 8 National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom. Electronic address: [email protected] , (United Kingdom)
  • 9 National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom. Electronic address: [email protected] , (United Kingdom)
  • 10 National Research Center "Institute of Immunology" FMBA Russia, 115478 Moscow, Russia. Electronic address: [email protected]
  • 11 National Heart and Lung Institute, Imperial College, SW7 2AZ London, United Kingdom. Electronic address: [email protected] , (United Kingdom)
  • 12 OOO "NPF "MATERIA MEDICA HOLDING", 129272 Moscow, Russia. Electronic address: [email protected]
  • 13 Research Institute of General Pathology and Pathophysiology, 125315 Moscow, Russia. Electronic address: [email protected]
Type
Published Article
Journal
Antiviral research
Publication Date
Jun 01, 2017
Volume
142
Pages
185–192
Identifiers
DOI: 10.1016/j.antiviral.2017.03.017
PMID: 28356234
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2'-5'-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-β), type II (IFN-γ) and type III (IFN-λ) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-А production and significantly decreased viral replication in vitro. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma. Copyright © 2017 Elsevier B.V. All rights reserved.

Report this publication

Statistics

Seen <100 times